These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 14722821)

  • 1. Practical consultations: multiple sclerosis.
    Wingerchuk DM; Carter JL
    Semin Neurol; 2003 Sep; 23(3):253-64. PubMed ID: 14722821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The BCTRIMS expanded consensus on treatment of multiple sclerosis: II. The evidences for the use of glucocorticoids and immunomodulatory treatments].
    Moreira MA; Lana-Peixoto MA; Callegaro D; Haussen SR; Gama PD; Gabbai AA; Rocha FC; Lino AM;
    Arq Neuropsiquiatr; 2002 Sep; 60(3-B):875-80. PubMed ID: 12364966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Betaseron: a breakthrough treatment for multiple sclerosis.
    Morrison W; Nelson J
    Can Nurse; 1996 Oct; 92(9):38-41. PubMed ID: 9118060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Still no evidence on the efficacy of immunomodulatory therapy in reducing functional impairment in multiple sclerosis].
    Vermeulen M
    Ned Tijdschr Geneeskd; 2007 Apr; 151(15):850-1. PubMed ID: 17472114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reproductive counselling, treatment and course of pregnancy in 73 German MS patients.
    Hellwig K; Brune N; Haghikia A; Müller T; Schimrigk S; Schwödiauer V; Gold R
    Acta Neurol Scand; 2008 Jul; 118(1):24-8. PubMed ID: 18205883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cause of familial multiple sclerosis].
    Wender MB
    Wiad Lek; 2002; 55(5-6):351-3. PubMed ID: 12235705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and disease modifying treatments in multiple sclerosis.
    Zajicek J
    Postgrad Med J; 2005 Sep; 81(959):556-61. PubMed ID: 16143683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapy of multiple sclerosis].
    Simó M
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):23-6. PubMed ID: 19731815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical testing of the treatment effect of interferon-beta Ia and Ib in multiple sclerosis].
    de Haan RJ; Polman CH
    Ned Tijdschr Geneeskd; 1996 Nov; 140(44):2168-71. PubMed ID: 8984352
    [No Abstract]   [Full Text] [Related]  

  • 13. Vogt-Koyanagi-Harada syndrome in a case of multiple sclerosis.
    Montero JA; Sanchis ME; Fernandez-Munoz M
    J Neuroophthalmol; 2007 Mar; 27(1):36-40. PubMed ID: 17414871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
    Kinkel RP; Kollman C; O'Connor P; Murray TJ; Simon J; Arnold D; Bakshi R; Weinstock-Gutman B; Brod S; Cooper J; Duquette P; Eggenberger E; Felton W; Fox R; Freedman M; Galetta S; Goodman A; Guarnaccia J; Hashimoto S; Horowitz S; Javerbaum J; Kasper L; Kaufman M; Kerson L; Mass M; Rammohan K; Reiss M; Rolak L; Rose J; Scott T; Selhorst J; Shin R; Smith C; Stuart W; Thurston S; Wall M;
    Neurology; 2006 Mar; 66(5):678-84. PubMed ID: 16436649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple sclerosis in children.
    Thomas T; Banwell B
    Semin Neurol; 2008 Feb; 28(1):69-83. PubMed ID: 18256988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response.
    Leyva L; Fernández O; Fedetz M; Blanco E; Fernández VE; Oliver B; León A; Pinto-Medel MJ; Mayorga C; Guerrero M; Luque G; Alcina A; Matesanz F
    J Neuroimmunol; 2005 Jun; 163(1-2):165-71. PubMed ID: 15885318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The future looks bright.
    Wende KE
    Rehab Manag; 1999; 12(2):32-4. PubMed ID: 10350900
    [No Abstract]   [Full Text] [Related]  

  • 18. Interferon beta, PHARMAC, and political directives: in the best interests of people with multiple sclerosis?
    McNaughton H; Kayes N; McPherson K
    N Z Med J; 2006 Apr; 119(1232):U1939. PubMed ID: 16633398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The treatment of multiple sclerosis with beta-interferon.
    Poser CM
    Neuroepidemiology; 2008; 31(3):157-8. PubMed ID: 18716413
    [No Abstract]   [Full Text] [Related]  

  • 20. Evidence-based medicine and clinical trials.
    Coyle PK
    Neurology; 2007 Jun; 68(24 Suppl 4):S3-7. PubMed ID: 17562847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.